Drug Delivery to Brain Tumours
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: closed (25 March 2022) | Viewed by 254
Special Issue Editor
2. Centre for Molecular and Medical Research, Deakin University, Geelong, VIC 3128, Australia
Interests: aptamers; drug development; novel therapeutics in cancer treatment; targeted drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
A key challenge in the treatment of brain tumours, either primary or secondary, is drug delivery to the brain. This is due to the unique anatomical structure and a distinctive microenvironment, cell types, and metabolism of the brain and the blood–brain barrier (BBB). Only 20% of brain tumours are primary—80% of them are secondary to other tumours such as lung, breast or melanoma. Despite rigorous scientific attempts to improve the treatment of these patients, current treatments, and invasive surgeries, radiotherapies, or chemotherapies, patients have a low survival rate and a poor quality of life. The aim of this Special Issue is to gather the latest discoveries in drug delivery to brain tumours. This includes improvements in understanding the biology of the brain and brain tumours, and novel methodologies in delivering drugs to these tumours. These methods include but are not limited to novel formulations of current therapeutics, application of aptamers, nanomedicines (lipid-based, polymer-based, or carbon based), biological vectors, invasive methods, and methods affecting the integrity of BBB. This Special Issue is open to cutting-edge research papers, case reports, and review papers.
Dr. Sarah Shigdar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- brain tumour
- brain metastasis
- brain drug delivery
- blood–brain barrier
- nanomedicine
- aptamer
